• C A Dionne, A M Camoratto, J P Jani, E Emerson, N Neff, J L Vaught, C Murakata, D Djakiew, J Lamb, S Bova, D George, and J T Isaacs.
• Cephalon Inc., West Chester, Pennsylvania 19380, USA. cdionne@cephalon.com
• Clin Cancer Res. 1998 Aug 1; 4 (8): 1887-98.

AbstractAdvanced prostate cancer remains largely incurable, primarily because the very low growth fraction present in these tumors makes them generally resistant to treatment with standard chemotherapeutic agents that target cell division. Effective therapies should therefore induce death of prostate cancer cells, independent of their growth rate. trkA, the high-affinity tyrosine kinase-linked receptor for nerve growth factor, has been implicated in prostatic cancer growth and may represent a molecular target for therapeutic agents. At low mg/kg doses, the trk tyrosine kinase inhibitor CEP-751 (KT6587) inhibits prostatic cancer growth in nine different animal models independent of the tumor growth rate, androgen sensitivity, metastatic ability, or state of tumor differentiation. CEP-751 is selective for cancerous versus normal prostate cells and affects the growth of only a limited number of nonprostate tumors. Importantly, CEP-751 induces cell death of prostate cancer cells in a cell cycle-independent fashion and, therefore, represents a novel therapeutic approach to the management of both hormone-dependent and hormone-independent prostate cancer.

43 keywords...

hide…